Adjuvant chemotherapy in stage IB NSCLC: implication of the new TNM staging system

Short review

Summary

Adjuvant chemotherapy (CT) became the standard of care for patients with completely resected non-small cell lung cancer. However, the evidence supports this intervention for stages II-IIIA only. For stage IB, the randomized trials were not able co configure a clear-cut conclusion. Positive results have been published by the Japanese investigators using uracil-tegafur, whereas no survival benefit was observed in the trials using platinum-based CT. The new TNM staging system adopted in 2009 operated some modifications which partially included the former stage IB. Despite the fact that the new staging system is currently in use, the recommendations regarding adjuvant CT, as they appear in the guidelines, are based on the evidence built on the previous TNM classification. Subsequently, the issue regarding adjuvant CT in stage IB deserves a new perspective. This paper will address the new viewpoint regarding adjuvant CT in stage IB, defined according to the current evidence and the amendments of new TNM staging system.

Keywords

NSCLC Stage IB Adjuvant chemotherapy TNM classification 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Crino L, Weder W, van Meerbeeck J. et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21(Suppl 5): v103–v115, 2010PubMedCrossRefGoogle Scholar
  2. Pisters K, Evans W, Azzoli G, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I–IIIA Resectable Non-Small-Cell Lung Cancer Guideline. J Clin Oncol, 25: 5506–5518, 2007PubMedCrossRefGoogle Scholar
  3. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst, 95: 1453–1461, 2003PubMedGoogle Scholar
  4. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350: 351–360, 2004PubMedCrossRefGoogle Scholar
  5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol, 7: 719–727, 2006PubMedCrossRefGoogle Scholar
  6. Butts C, Ding K, Seymour L, et al. Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol, 28: 29–34, 2010PubMedCrossRefGoogle Scholar
  7. Pignon J, Tribodet H, Scagliotti G, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol, 26: 3552–3559, 2008PubMedCrossRefGoogle Scholar
  8. Strauss G, Herndon J, Maddaus M, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol, 26: 5043–5051, 2008PubMedCrossRefGoogle Scholar
  9. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2: 706–714, 2007PubMedCrossRefGoogle Scholar
  10. Detterbeck F, Boffa D, Tanoue L, et al. The new lung cancer staging System. Chest, 136: 260–271, 2009PubMedCrossRefGoogle Scholar
  11. Ou I, Zell J, Ziogas A, et al. Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest, 133: 662–669, 2008PubMedCrossRefGoogle Scholar
  12. Padilla J, Calvo V, Penalver JC, et al. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg, 63: 324–326, 1997PubMedCrossRefGoogle Scholar
  13. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumor in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109: 120–129, 1995PubMedCrossRefGoogle Scholar
  14. Wu YC, Lin CF, Hsu WH, et al. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg, 24: 994–1001, 2003PubMedCrossRefGoogle Scholar
  15. Han H, Silverman J, Santucci T, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol, 8: 72–79, 2005CrossRefGoogle Scholar
  16. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg, 129: 87–93, 2005PubMedCrossRefGoogle Scholar
  17. Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J, 26: 480–486, 2005PubMedCrossRefGoogle Scholar
  18. Horn L, Sandler A, Putnam J. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. J Thorac Oncol, 2: 377–383, 2007PubMedCrossRefGoogle Scholar
  19. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355: 983–991, 2006PubMedCrossRefGoogle Scholar
  20. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med, 355: 570–580, 2006PubMedCrossRefGoogle Scholar
  21. Chen HY, Yu SL, Chen Ch, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med, 356: 11–20, 2007PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  1. 1.Medical Oncology DepartmentInstitute of Oncology Alexandru TrestioreanuBucharestRomania

Personalised recommendations